FRA:5CV • NL0015436031
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CUREVAC NV (5CV.DE).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2021-06-17 | B of A Securities | Downgrade | Buy -> Neutral |
| 2021-04-26 | Guggenheim | Initiate | Buy |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 67.4M -34.56% | 53.758M -20.24% | 535.18M 895.54% | 72.687M -86.42% | 89.921M 23.71% | 151.53M 68.51% | 201.05M 32.68% | 253.93M 26.30% | 293.89M 15.74% | 306.03M 4.13% | 197.66M -35.41% | |
| EBITDA YoY % growth | -201.3M 56.52% | -247.497M -22.95% | 196.491M 179.39% | -113.447M -157.74% | -113.488M -0.04% | -32.747M 71.14% | 223.37M 782.11% | 324.72M 45.37% | 422.96M 30.25% | N/A | N/A | |
| EBIT YoY % growth | -225M 53.00% | -270.883M -20.39% | 177.682M 165.59% | -137.999M -177.67% | -97.158M 29.59% | -58.146M 40.15% | 49.397M 184.95% | 99.982M 102.41% | 135.32M 35.34% | 144.48M 6.77% | 31.104M -78.47% | |
| Operating Margin | -333.83% | -503.89% | 33.20% | -189.85% | -108.05% | -38.37% | 24.57% | 39.37% | 46.04% | 47.21% | 15.74% | |
| EPS YoY % growth | -1.24 61.67% | -1.18 4.84% | 0.73 161.86% | -0.47 -163.99% | -0.44 6.55% | -0.10 77.80% | -0.54 -460.42% | -0.55 -1.90% | -0.56 -1.84% | N/A | N/A |
All data in EUR
| Q4 / 25 | |
|---|---|
| EPS Q2Q % growth | 0.05 138.85% |
| Revenue Q2Q % growth | 44.778M 209.48% |
| EBITDA Q2Q % growth | -25.422M -1.89% |
| EBIT Q2Q % growth | 7.639M 117.46% |
All data in EUR
11 analysts have analysed 5CV.DE and the average price target is 4.02 EUR. This implies a price increase of 3.22% is expected in the next year compared to the current price of 3.892.
CUREVAC NV (5CV.DE) will report earnings on 2026-04-08, after the market close.
The consensus EPS estimate for the next earnings of CUREVAC NV (5CV.DE) is 0.05 EUR and the consensus revenue estimate is 44.78M EUR.
The number of analysts covering CUREVAC NV (5CV.DE) is 11.